Literature DB >> 10508016

Pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration.

D Breilh1, B Allaouchiche, H Jaumain, P Boulétreau, D Chassard, I Malbec, D Ducint, M C Saux.   

Abstract

The objective of this study was to analyze the pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration. Six patients received 15 mg of isepamicin per kg of body weight. The mean isepamicin concentration peak in serum was 62.88 +/- 18.20 mg/liter 0.5 h after the infusion. The elimination half-life was 7. 91 +/- 0.83 h. The mean total body clearance was 1.75 +/- 0.28 liters/h, and dialysate outlet (DO) clearance was 2.76 +/- 0.59 liters/h. The mean volume of distribution was 19.83 +/- 2.95 liters. The elimination half-life, DO clearance, and volume of distribution were almost constant. In this group of patients, the initial dosage of 15 mg/kg appeared to be adequate, but the dosage interval should be determined by monitoring residual isepamicin concentrations in plasma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508016      PMCID: PMC89492          DOI: 10.1128/AAC.43.10.2409

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  [Pharmacokinetic and clinical studies on isepamicin in chronic complicated urinary tract infection using daily single dose treatment].

Authors:  K Suzuki; M Horiba; Y Nagata
Journal:  Jpn J Antibiot       Date:  1990-09

2.  Survival in patients treated with continuous arteriovenous hemodialysis for acute renal failure and chronic renal failure. Preliminary observations.

Authors:  R P Geronemus; N S Schneider; M Epstein
Journal:  Contrib Nephrol       Date:  1991       Impact factor: 1.580

Review 3.  Pharmacokinetics of continuous renal replacement therapy.

Authors:  M Schetz; P Ferdinande; G Van den Berghe; C Verwaest; P Lauwers
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

4.  Evaluation of a fluorescence polarization immunoassay procedure for quantitation of isepamicin, a new aminoglycoside antibiotic.

Authors:  T Uematsu; A Mizuno; Y Suzuki; R Sato; T Yamazaki; M Nakashima
Journal:  Ther Drug Monit       Date:  1988       Impact factor: 3.681

5.  A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.

Authors:  F Mentré; R Gomeni
Journal:  J Biopharm Stat       Date:  1995-07       Impact factor: 1.051

Review 6.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

7.  Optimal sampling times for pharmacokinetic experiments.

Authors:  D Z D'Argenio
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

8.  Population pharmacokinetic study of isepamicin with intensive care unit patients.

Authors:  M Tod; C Padoin; C Minozzi; J Cougnard; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Isepamicin disposition in subjects with various degrees of renal function.

Authors:  C E Halstenson; J S Kelloway; M B Affrime; C C Lin; M A Teal; B E Shapiro; W M Awni
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics during continuous haemofiltration.

Authors:  F Bressolle; J M Kinowski; J E de la Coussaye; N Wynn; J J Eledjam; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.